Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00634283 · ClinicalTrials.gov registry record · Phase 4
Study of the Effects of an Antidepressant Medication and Placebo on the Brain Functioning of Normal Subjects
A Phase 4 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT00634283: Completed Phase 4 study, sponsored by University of California, Los Angeles.
NCT00634283 is a Phase 4 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 6 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00634283, a Phase 4 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study examines the effects of an antidepressant medication and placebo on the brain functioning of normal subjects. In this study, recordings of brain electrical activity are being used to detect and monitor the response to treatment with venlafaxine IR (Effexor), a drug used for the treatment of depression. The intent of this study is to test specific hypotheses regarding: 1. long-term brain effects of a single course of antidepressant treatment 2. pharmaco-conditioning effects underlying antidepressant tolerance/sensitization 3. brain functional response to initial versus subsequent antidepressant trials in normal healthy subjects.
Primary Outcome
Cordance values were calculated from conventional 'absolute' and 'relative' qEEG power measures using a three-step procedure. First, EEG power values were computed using a re-attributional electrode montage. Second, the absolute and relative power values were z-transformed to measure deviation from the mean values for each electrode site s in each frequency band f for that recording, yielding Anorm(s,f) and Rnorm(s,f), respectively. Third, these z-scores were summed to yield a cordance "intensit
Interventions
- DRUG venlafaxine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2008-02 |
| Est. Completion | 2009-02 |
| Phase | Phase 4 |
What the finished NCT00634283 record still lists
NCT00634283 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which venlafaxine is the first listed.
NCT00634283 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00634283 about?
NCT00634283 is a clinical study titled "Study of the Effects of an Antidepressant Medication and Placebo on the Brain Functioning of Normal Subjects". This study examines the effects of an antidepressant medication and placebo on the brain functioning of normal subjects. In this study, recordings of brain electrical activity are being used to detect and monitor the response to treatment with venlafaxine IR (Effexor), a drug used for the treatment ...
What is the current status of trial NCT00634283?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2008-02. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00634283?
The interventions under investigation include: venlafaxine (DRUG).
Who is sponsoring clinical trial NCT00634283?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00634283's enrollment target sits among peer trials
6 1983rd of 2000 higher than 12 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia